Discovery of 1,2,4-triazine derivatives as adenosine A 2A antagonists using structure based drug design

Journal of Medicinal Chemistry

Volumn 55, Issue 5, 2012, Pages 1898-1903

  Congreve, Miles ^a   Andrews, Stephen P ^a   Doré, Andrew S ^a   Hollenstein, Kaspar ^a   Hurrell, Edward ^a   Langmead, Christopher J ^a   Mason, Jonathan S ^a   Ng, Irene W ^a   Tehan, Benjamin ^a   Zhukov, Andrei ^a   Weir, Malcolm ^a   Marshall, Fiona H ^a  

^a Heptares Therapeutics Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,4 TRIAZINE DERIVATIVE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; G PROTEIN COUPLED RECEPTOR; HALOPERIDOL; ISTRADEFYLLINE; LIGAND;

ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG STRUCTURE; HUMAN; IN VIVO STUDY; PARKINSON DISEASE; X RAY CRYSTALLOGRAPHY;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ADMINISTRATION, ORAL; ANIMALS; ANTIPARKINSON AGENTS; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION; PYRIDINES; RADIOLIGAND ASSAY; RATS; RECEPTOR, ADENOSINE A2A; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PLASMON RESONANCE; TRIAZINES;

EID: 84858034356     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201376w     Document Type: Article

References (17)

1. 2A receptor antagonists for the treatment of Parkinson's disease Curr. Opin. Drug Discovery Dev. 2010, 13, 466-480
2. 2A receptor antagonist for the potential treatment of parkinsonism and other disorders IDrugs 2010, 13, 723-731
3. 2A Receptor Antagonists by Virtual Screening. Just accepted. DOI: 10.1021/jm201455y. Published online: January 17, 2012
4. 2A Receptor J. Med. Chem. 2011, 54, 4312-4323
5. 2A Crystal Structure Tell Us? Curr. Top. Med. Chem. 2010, 93, 993-1018
6. 2A agonists and antagonists J. Med. Chem. 2003, 46, 4847-4859
7. Ballesteros, J. A.; Weinstein, H.; Stuart, C. S. Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G protein coupled receptors. In Methods in Neurosciences; Academic Press: New York, 1995; Vol. 25, pp 366-428.
8. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules J. Med. Chem. 1985, 28, 849-857
9. Sciabola, S.; Stanton, R. V.; Mills, J. E.; Flocco, M. M.; Baroni, M.; Cruciani, G.; Perruccio, F.; Mason, J. S. High-throughput virtual screening of proteins using GRID molecular interaction fields J. Chem. Inf. Model. 2010, 50, 155-169
10. 2A receptor in complex with ZM241385 and the xanthines XAC and caffeine Structure 2011, 19, 1283-1293
11. J. Takagi, J.; Sato, K.; Hartwig, J. F.; Ishiyama, T.; Miyaura, N. Iridium-catalyzed C-H coupling reaction of heteroaromatic compounds with bis(pinacolato)diboron: regioselective synthesis of heteroarylboronates Tetrahedron Lett. 2002, 43, 5649-5651
12. Murphy, J. M.; Liao, X.; Hartwig., J. F. Meta Halogenation of 1,3-Disubstituted Arenes via Iridium-Catalyzed Arene Borylation J. Am. Chem. Soc. 2007, 129, 15434-15435
13. Ishiyama, T.; Takagi, J.; Nobuta, Y.; Miyaura., N. Iridium-catalyzed C-H borylation of arenes and heteroarenes: 1-chloro-3-iodo-5-(4,4,5,5-tetramethyl-1, 3,2-dioxaborolan-2-yl)benzene and 2-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2- yl)indole Org. Synth. 2005, 82, 126-132
14. 2A receptor structures reveal common features of GPCR activation Nature 2011, 474, 521-523
15. 2A receptor ACS Med. Chem. Lett. 2010, 1, 160-164
16. Congreve, M.; Langmead, C. J.; Mason, J. S.; Marshall, F. H. Progress in Structure Based Drug Design for G Protein-Coupled Receptors J. Med. Chem. 2011, 54, 4283-4311
17. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431